Severe asthma and quality of life

Table 1 Biologics currently in development or approved for the treatment of asthma

Drug	Target	Biomarkers	Effects	Route/Dose
Omalizumab	IgE	Ag-specific IgE Better responses with higher FeNO and blood eosinophils >300 cells/ uL	Decreased asthma exacerbations	150–375 mg SC q2-q4wks; frequency based on IgE and body weight
Mepolizumab	IL-5	Blood eosinophil count >150 cells/uL at initiation or 300 cells/uL in past year	Decreased asthma exacerbations; Improvement in FEV1	100 mg SC q4wk.
Reslizumab	IL-5	Blood eosinophil count >400 cells/uL	Decreased asthma exacerbations; Improvement in FEV1	3 mg/kg IV q4wks
Benralizumab	IL-5Rα	Blood eosinophil count >300 cells/ uL	Decreased asthma exacerbations; Improvement in FEV1.	30 mg SC q4wks ×3 then q8wks
Tralokinumab	IL-13	Elevated blood periostin and DDP-4	Improvement in FEV1	Not Defined
Dupilumab	IL-4Rα	Better responses with blood eosinophil count >300 cells/ uL	Decreased asthma exacerbations; Improvement in FEV1	200 or 300 mg SC q2wks; administered at home

DDP-4 dipeptidyl peptidase-4, FeNo fractional excretion of nitric oxide, FEV1 forced expiratory volume in 1 s

ISSN: 1939-4551